These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36051029)

  • 1. Unmet needs in the management of immune-mediated thrombotic thrombocytopenic purpura and the potential role of caplacizumab in the UK-A modified-Delphi study.
    Scully M; Dutt T; Lester W; Farrington E; Lockwood S; Perry R; Holmes S
    EJHaem; 2022 Aug; 3(3):619-627. PubMed ID: 36051029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience.
    Tse B; Buchholz M; Pavenski K
    Platelets; 2023 Dec; 34(1):2157807. PubMed ID: 36636834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons.
    Seguí IG; Mingot Castellano ME; Izquierdo CP; de la Rubia J
    Expert Rev Hematol; 2024; 17(1-3):9-25. PubMed ID: 38353182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?
    Picod A; Veyradier A; Coppo P
    J Thromb Haemost; 2021 Jan; 19(1):58-67. PubMed ID: 33236389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.
    Völker LA; Kaufeld J; Balduin G; Merkel L; Kühne L; Eichenauer DA; Osterholt T; Hägele H; Kann M; Grundmann F; Kolbrink B; Schulte K; Gäckler A; Kribben A; Boss K; Potthoff SA; Rump LC; Schmidt T; Mühlfeld AS; Schulmann K; Hermann M; Gaedeke J; Sauerland K; Bramstedt J; Hinkel UP; Miesbach W; Bauer F; Westhoff TH; Bruck H; Buxhofer-Ausch V; Müller TJ; Wendt R; Harth A; Schreiber A; Seelow E; Tölle M; Gohlisch C; Bieringer M; Geuther G; Jabs WJ; Fischereder M; von Bergwelt-Baildon A; Schönermarck U; Knoebl P; Menne J; Brinkkoetter PT;
    J Thromb Haemost; 2023 Mar; 21(3):559-572. PubMed ID: 36696206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.
    Poullin P; Bornet C; Veyradier A; Coppo P
    Drugs Today (Barc); 2019 Jun; 55(6):367-376. PubMed ID: 31250841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab.
    Bowyer A; Brown P; Hopkins B; Scully M; Shepherd F; Lowe A; Mensah P; Maclean R; Kitchen S; van Veen JJ
    Br J Haematol; 2022 May; 197(3):349-358. PubMed ID: 35262910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment.
    le Besnerais M; Veyradier A; Benhamou Y; Coppo P
    Expert Opin Biol Ther; 2019 Nov; 19(11):1127-1134. PubMed ID: 31359806
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, Therapy and Open Issues.
    Trisolini SM; Laganà A; Capria S
    Mediterr J Hematol Infect Dis; 2024; 16(1):e2024060. PubMed ID: 38984099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report.
    Schwaegermann MK; Hobohm L; Rausch J; Reuter M; Griemert TF; Sivanathan V; Falter T; Sprinzl MF; Lackner KJ; Galle PR; Konstantinides S; Theobald M; von Auer C
    Hamostaseologie; 2023 Jun; 43(3):215-218. PubMed ID: 34327693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world experience with caplacizumab in the management of acute TTP.
    Dutt T; Shaw RJ; Stubbs M; Yong J; Bailiff B; Cranfield T; Crowley MP; Desborough M; Eyre TA; Gooding R; Grainger J; Hanley J; Haughton J; Hermans J; Hill Q; Humphrey L; Lowe G; Lyall H; Mohsin M; Nicolson PLR; Priddee N; Rampotas A; Rayment R; Rhodes S; Taylor A; Thomas W; Tomkins O; Van Veen JJ; Lane S; Toh CH; Scully M
    Blood; 2021 Apr; 137(13):1731-1740. PubMed ID: 33150355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura.
    Kühne L; Kaufeld J; Völker LA; Wendt R; Schönermarck U; Hägele H; Osterholt T; Eichenauer DA; Bieringer M; von Bergwelt-Baildon A; Fischereder M; Buxhofer-Ausch V; Menne J; Brinkkoetter PT; Knöbl P
    J Thromb Haemost; 2022 Apr; 20(4):951-960. PubMed ID: 35000278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy.
    Mingot-Castellano ME; García-Candel F; Martínez-Nieto J; García-Arroba J; de la Rubia-Comos J; Gómez-Seguí I; Paciello-Coronel ML; Valcárcel-Ferreiras D; Jiménez M; Cid J; Lozano M; García-Gala JM; Angós-Vazquez S; Vara-Pampliega M; Guerra-Domínguez L; Ávila-Idrobo LF; Oliva-Hernandez A; Zalba-Marcos S; Tallón-Ruiz I; Ortega-Sánchez S; Goterris-Viciedo R; Moreno-Jiménez G; Domínguez-Acosta L; Araiz-Ramírez M; Hernández-Mateos L; Flores-Ballesteros E; Del Río-Garma J; Pascual-Izquierdo C
    Blood; 2024 May; 143(18):1807-1815. PubMed ID: 38237147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
    Peyvandi F; Scully M; Kremer Hovinga JA; Cataland S; Knöbl P; Wu H; Artoni A; Westwood JP; Mansouri Taleghani M; Jilma B; Callewaert F; Ulrichts H; Duby C; Tersago D;
    N Engl J Med; 2016 Feb; 374(6):511-22. PubMed ID: 26863353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
    Peyvandi F; Scully M; Kremer Hovinga JA; Knöbl P; Cataland S; De Beuf K; Callewaert F; De Winter H; Zeldin RK
    J Thromb Haemost; 2017 Jul; 15(7):1448-1452. PubMed ID: 28445600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caplacizumab in paediatric immune thrombotic thrombocytopenic purpura (iTTP): the UK TTP Registry experience.
    Taylor AM; Keogh L; Dickens EL; Dutt T; Grainger J; Gregory R; Mapplebeck C; Richards M; Stokley S; Salta S; Taylor T; Scully M
    Blood Adv; 2024 Jul; ():. PubMed ID: 38968147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era.
    Prasannan N; Thomas M; Stubbs M; Westwood JP; de Groot R; Singh D; Scully M
    Blood; 2023 May; 141(18):2206-2213. PubMed ID: 36720103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Cell Directed Therapy for Immune Thrombotic Thrombocytopenic Purpura (iTTP).
    Chen M; Shortt J
    Transfus Med Rev; 2022 Oct; 36(4):204-214. PubMed ID: 36396570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. True vs. false immune-mediated thrombotic thrombocytopenic purpura exacerbations: a clinical case in the caplacizumab era.
    Laganà A; Trisolini SM; Maglione R; Mahnaz SB; Imperatore S; Vitullo D; Capria S
    Blood Coagul Fibrinolysis; 2024 Jan; 35(1):37-42. PubMed ID: 37994623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura.
    Kubo M; Matsumoto M
    Int J Hematol; 2023 Mar; 117(3):331-340. PubMed ID: 36757521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.